¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ±Ô¸ð ºÐ¼® : Ä¡·á À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Substance Abuse Treatment Market Size study, by Treatment Type (Tobacco/Nicotine & Vaping, Alcohol), End-use (Rehabilitation Centers, Clinics, Hospitals), and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1739068
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 285 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ ¾à 111¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£ Áß(2024-2032³â) 9.05%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¾à¹° ³²¿ë Ä¡·á¸¦ µÑ·¯½Ñ ȯ°æÀº Áßµ¶ÀÌ µµ´öÀû ½ÇÆÐ°¡ ¾Æ´Ï¶ó ¸¸¼ºÀûÀ̰í Àç¹ßÀÌ ¹Ýº¹µÇ´Â ³ú ÁúȯÀ̶ó´Â ÀνÄÀÌ È®»êµÇ¸é¼ ¿ªµ¿ÀûÀÌ°í ´Ù¸éÀûÀÎ »ýŰè·Î ÁøÈÇϰí ÀÖ½À´Ï´Ù. ¾ËÄÚ¿Ã, ´ÏÄÚÆ¾, ¾à¹° ÀÇÁ¸ÀÌ Àü ¼¼°è¿¡¼ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ½Ã½ºÅÛ°ú ¹Î°£ ÀÌÇØ°ü°èÀÚµéÀº Á¶±â °³ÀÔ°ú Áõ°Å¿¡ ±â¹ÝÇÑ Ä¡·á ¸ðµ¨¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÇ·áÀû ÇØµ¶, ¾à¹° º¸Á¶ ¿ä¹ý(MAT), Çൿ °³ÀÔÀÌ ÅëÇյǾî Á¾ÇÕÀûÀÎ Ä¡·á ÇÁ·ÎÅäÄÝÀÌ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ Ä¡·áÇÐ ¹× ¿ø°Ý ÀçȰ Ç÷§ÆûÀº Áßµ¶ ȸº¹ ¿©Á¤ÀÇ Á¢±Ù¼º°ú °³ÀÎȸ¦ Çö´ëÈÇϰí ÀÖ½À´Ï´Ù.
´ÏÄÚÆ¾ Áßµ¶, VAPE Áßµ¶, ¾ËÄÚ¿Ã ³²¿ëÀÇ À¯ÇàÀº ƯÈ÷ ÆÒµ¥¹Í ÀÌÈÄ ´õ¿í µÎµå·¯Áö°Ô ³ªÅ¸³ª¸é¼ È®Àå °¡´ÉÇϰí È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¾à¹° ÇÇÇØ °¨¼Ò Àü·«À» Áö¿øÇϱâ À§ÇØ °øÁß º¸°Ç Á¤Ã¥ÀÌ °ÈµÇ°í Á¤ºÎ¿Í ºñ¿µ¸® ´Üü´Â Áõ°¡ÇÏ´Â Àç¹ß·ü°ú °ú´Ù º¹¿ëÀ¸·Î ÀÎÇÑ »ç¸Á·ü¿¡ ´ëóÇϱâ À§ÇØ ¸¹Àº ÀÚ±ÝÀ» ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀº ºÎÇÁ·¹³ë¸£ÇÉ, ³ªÆ®·º¼Õ, µð¼³ÇǶ÷°ú °°Àº Â÷¼¼´ë ¾à¹°·Î MAT¸¦ Çõ½ÅÇϰí ÀÖÀ¸¸ç, ¸¹Àº °æ¿ì ÀÎÁöÇൿġ·á¿Í °áÇÕÇÏ¿© ÀüÀÎÀû Ä¡À¯¸¦ º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀçȰ ÇÁ·Î±×·¥Àº ȯÀÚÀÇ Æ¯¼º, Á¤½ÅÁúȯ µ¿¹Ý ¿©ºÎ, »çȸ°æÁ¦Àû ¹è°æ µî¿¡ µû¶ó Á¶Á¤µÇ°í ÀÖÀ¸¸ç, ±× °á°ú Ä¡·á ¼º°ú¿Í ¼øÀÀµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ ¼ºÀå¼¼¿¡µµ ºÒ±¸ÇÏ°í ½ÃÀåÀº »ó´çÇÑ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ³ôÀº Ä¡·áºñ, »çȸÀû Æí°ß, Àü¹® ÀçȰ¼¾ÅÍ¿¡ ´ëÇÑ ÆíÇâµÈ Á¢±Ù¼º(ƯÈ÷ ÀÇ·á ¼ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª) µîÀÌ ½ÃÀå¿¡ ¿øÈ°ÇÏ°Ô Ä§ÅõÇÏ´Â °ÍÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Á¤½ÅÀÇ·áÀÇ Æòµî¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, ¾à¹°»ç¿ëÀå¾Ö(SUD) Ä¡·á¿¡ ´ëÇÑ º¸Çè ȯ±ÞÀÌ È®´ëµÇ¸é¼ Á¢±Ù¼º È®´ëÀÇ ±âÆøÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ½Å°æ°úÇаú ´º·ÎÇǵå¹é ÅøÀÇ ¹ßÀüµµ ȸº¹ °úÁ¤ÀÇ º¸Á¶ Ä¡·á·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüµÈ Ä¡·á¹ýÀº ȯÀÚ ¸ð´ÏÅ͸µ°ú Àç¹ß ¿¹ÃøÀ» °ÈÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ÀÔ¿ø ¹× ¿Ü·¡ ȯÀÚ ¸ðµÎ¿¡¼ º¸´Ù Á¤È®ÇÏ°í ¸ÂÃã Ä¡·áÀÇ Æ²À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ÆÇ¸Å ä³ÎÀº Á¡Á¡ ´õ ´Ù¾çÇØÁö°í ÀÖÀ¸¸ç, ÀçȰ¼¾ÅÍ, Á¤½Å°ú Ŭ¸®´Ð, Áö¿ª ÀÇ·á ÇÁ·Î±×·¥, º´¿ø µîÀÌ 360µµ Ä¡·á¸¦ À§ÇØ ´ÙÇÐÁ¦ ÆÀÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¿Ü·¡ ȯÀÚ ¼ºñ½º´Â ºñ¿ë È¿À²¼º°ú À¯¿¬¼ºÀ¸·Î ÀÎÇØ ±Þ°ÝÇÑ »ó½Â °î¼±À» ±×¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°Ý Á¤½ÅÀÇÇÐ ¹× ¸ð¹ÙÀÏ ¾ÛÀ» ÅëÇÑ ±â¼ú ±â¹ÝÀÇ Ä¡·á¹ý Á¦°øÀº ȯÀÚ Âü¿©, º¹¾à ¼øÀÀµµ, »çÈÄ °ü¸® Áö¿ø¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ´Ü±â ¹× Àå±â ȸº¹ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¼¾ÅÍ´Â ÀÎÇÁ¶ó¸¦ È®ÀåÇϰí, Àü·«Àû Á¦ÈÞ¸¦ ¸Î°í, ÅëÇÕ µðÁöÅÐ Ç÷§Æû¿¡ ÅõÀÚÇÏ¿© ¿î¿µ ¹× ȯÀÚ °ü¸®¸¦ °£¼ÒÈÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ SAMHSA¿Í °°Àº °·ÂÇÑ Á¤ºÎ Áö¿ø ±¸»ó, ÀǷẸÇèÀÇ º¸±Þ, ³ôÀº SUD À¯º´·ü¿¡ ÈûÀÔ¾î Àü ¼¼°è ¾à¹° ³²¿ë Ä¡·á ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ÷´ÜÀÎ ÀÇ·á Á¤Ã¥°ú ¾ËÄÚ¿Ã Áßµ¶·ü Áõ°¡¿¡ ÈûÀÔ¾î ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ´ëÁßÀÇ ÀÎ½Ä °³¼± Ä·ÆäÀÎ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó È®´ë, Àεµ¿Í Áß±¹ µîÀÇ Ã»¼Ò³â ¾à¹° ³²¿ë·ü Áõ°¡¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â Áö¿ª ±â¹Ý Áßµ¶ Ä¡·á ÇÁ·Î±×·¥ ¹× Áö¿ø ³×Æ®¿öÅ©¿¡ ´ëÇÑ ÅõÀÚ°¡ È®´ëµÇ¸é¼ À¯¸ÁÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå : °³¿ä
- ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð
Á¦2Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå : Á¤ÀÇ¿Í ºÐ¼® ÀüÁ¦
- ºÐ¼® ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ
- ºÐ¼® ÀüÁ¦
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ »çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ±¸Á¶
- ½ÃÀå °æÀï
- °æÁ¦Àû ½ÇÇö °¡´É¼º(ÇÁ·Î¹ÙÀÌ´õÀÇ ½ÃÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ±¸Á¶
- ±â¼ú Áøº¸
- »çȸÀû ¹× ¹®ÈÀû ¹è·Á
- ȯÀÚÀÇ Àνİú ¼ö¿ë
- ºÐ¼® ¹æ¹ý
- ºÐ¼® ´ë»ó ±â°£
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå : »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷ °£ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ÇâÈÄ ¾îÇÁ·ÎÄ¡
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡Àû ¿äÀÎ
- °æÁ¦Àû ¿äÀÎ
- »çȸÀû ¿äÀÎ
- ±â¼úÀû ¿äÀÎ
- ȯ°æÀû ¿äÀÎ
- ¹ýÀû ¿äÀÎ
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû º¯ÈÀÇ µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð
Á¦5Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Ä¡·á À¯Çüº°(2022-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¸ÅÃâ µ¿Ç⠺м® : Ä¡·á À¯Çüº°(2022³â¡¤2032)
- ´ã¹è/´ÏÄÚÆ¾, ÀüÀÚ´ã¹è
- ¾ËÄÚ¿Ã
Á¦6Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2022-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¸ÅÃâ µ¿Ç⠺м® : ÃÖÁ¾ ¿ëµµº°(2022³â¡¤2032)
Á¦7Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022-2032³â)
- ºÏ¹Ì ½ÃÀå
- À¯·´ ½ÃÀå
- ¿µ±¹ ½ÃÀå
- µ¶ÀÏ ½ÃÀå
- ÇÁ¶û½º ½ÃÀå
- ½ºÆäÀÎ ½ÃÀå
- ÀÌÅ»¸®¾Æ ½ÃÀå
- ±âŸ À¯·´ ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
- Áß±¹ ½ÃÀå
- Àεµ ½ÃÀå
- ÀϺ» ½ÃÀå
- È£ÁÖ ½ÃÀå
- Çѱ¹ ½ÃÀå
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
- ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå
- »ç¿ìµð¾Æ¶óºñ¾Æ ½ÃÀå
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹ ½ÃÀå
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå
Á¦8Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- Mallinckrodt Pharmaceuticals
- Pfizer Inc.
- Teva Pharmaceuticals
- ÁÖ¿ä ½ÃÀåÀÇ Àü·«
- ±â¾÷ °³¿ä
- Mallinckrodt Pharmaceuticals
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó Á¦°ø)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Pfizer Inc.
- Teva Pharmaceuticals
- Alkermes plc
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Indivior PLC
- Glenmark Pharmaceuticals
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Purdue Pharma L.P.
- H. Lundbeck A/S
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- BioCorRx Inc.
Á¦9Àå ºÐ¼® ÇÁ·Î¼¼½º
- ºÐ¼® ÇÁ·Î¼¼½º
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ¿¹Ãø
- °ËÁõ
- °£Çà
- ºÐ¼® ¼Ó¼º
KSA
¿µ¹® ¸ñÂ÷
Global Substance Abuse Treatment Market is valued approximately at USD 11.18 billion in 2023 and is projected to grow at a compelling CAGR of 9.05% over the forecast period 2024-2032. The substance abuse treatment landscape has evolved into a dynamic and multifaceted ecosystem fueled by a deepening understanding of addiction as a chronic, relapsing brain disease rather than a moral failing. With an alarming global increase in alcohol, nicotine, and drug dependence, healthcare systems and private stakeholders are leaning into early intervention and evidence-based therapeutic models. Medical detoxification, medication-assisted therapies (MAT), and behavioral interventions are increasingly integrated to form comprehensive treatment protocols. Moreover, digital therapeutics and tele-rehab platforms are modernizing the accessibility and personalization of addiction recovery journeys.
The prevalence of nicotine addiction, vaping dependencies, and alcohol abuse-especially post-pandemic-has significantly intensified demand for scalable, effective treatments. Concurrently, public health policies are being fortified to support harm-reduction strategies, while governments and non-profit organizations are allocating substantial funding to tackle rising relapse rates and overdose fatalities. Pharmaceutical companies are innovating across MATs with next-gen formulations of drugs such as buprenorphine, naltrexone, and disulfiram, often combined with cognitive behavioral therapy to ensure holistic healing. Furthermore, rehabilitation programs are increasingly being tailored based on patient demographics, co-occurring mental health disorders, and socio-economic background, thereby improving outcomes and compliance.
Despite its momentum, the market faces considerable challenges. High treatment costs, social stigmatization, and uneven access to specialized rehab centers-particularly in underserved regions-hinder seamless market penetration. However, a burgeoning awareness of mental health parity and insurance reimbursements for substance use disorder (SUD) treatments are acting as catalysts for expanded access. Advances in neuroscience and neurofeedback tools are also emerging as adjunct therapies in the recovery process. These evolving modalities not only enhance patient monitoring and relapse prediction but also facilitate more accurate, personalized treatment frameworks across both in-patient and outpatient settings.
Sales channels are becoming increasingly diversified, with rehab centers, psychiatric clinics, community health programs, and hospitals integrating multidisciplinary teams for 360-degree care. Outpatient services, in particular, are witnessing a steep upward curve due to their cost-effectiveness and flexibility. Moreover, technology-enabled therapy delivery-via telepsychiatry and mobile apps-is revolutionizing patient engagement, medication adherence, and aftercare support. As demand rises for both short-term and long-term recovery programs, treatment centers are scaling up their infrastructure, forging strategic alliances, and investing in integrated digital platforms to streamline operations and patient care.
Regionally, North America dominates the global substance abuse treatment market, buoyed by robust government-funded initiatives like SAMHSA, widespread health insurance coverage, and a high prevalence of SUDs. Europe follows closely, propelled by progressive healthcare policies and rising alcohol dependency rates. Meanwhile, Asia Pacific is poised for the fastest growth over the forecast period, driven by increasing public awareness campaigns, expanding healthcare infrastructure, and rising rates of youth substance abuse in countries such as India and China. Latin America and the Middle East & Africa are emerging as promising frontiers with growing investments in community-based addiction treatment programs and support networks.
Major market player included in this report are:
- Mallinckrodt Pharmaceuticals
- Pfizer Inc.
- Teva Pharmaceuticals
- Alkermes plc
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Indivior PLC
- Glenmark Pharmaceuticals
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Purdue Pharma L.P.
- H. Lundbeck A/S
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- BioCorRx Inc.
The detailed segments and sub-segment of the market are explained below:
By Treatment Type
- Tobacco/Nicotine & Vaping
- Alcohol
By End-use
- Rehabilitation Centers
- Clinics
- Hospitals
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Substance Abuse Treatment Market Executive Summary
- 1.1. Global Substance Abuse Treatment Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Treatment Type
- 1.3.2. By End-use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Substance Abuse Treatment Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Provider Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Social & Cultural Considerations
- 2.3.4.4. Patient Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Substance Abuse Treatment Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising prevalence of alcohol and nicotine dependence
- 3.1.2. Increased public funding and policy support for SUD treatment
- 3.1.3. Integration of digital therapeutics and tele-rehab platforms
- 3.2. Market Challenges
- 3.2.1. High treatment costs and reimbursement hurdles
- 3.2.2. Social stigma and low treatment-seeking behavior
- 3.2.3. Uneven access across rural and underserved regions
- 3.3. Market Opportunities
- 3.3.1. Expansion of outpatient and community-based programs
- 3.3.2. Innovation in medication-assisted therapies (MAT)
- 3.3.3. Strategic alliances between pharma and rehab providers
Chapter 4. Global Substance Abuse Treatment Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Substance Abuse Treatment Market Size & Forecasts by Treatment Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Revenue Trend Analysis by Treatment Type, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Tobacco/Nicotine & Vaping
- 5.2.2. Alcohol
Chapter 6. Global Substance Abuse Treatment Market Size & Forecasts by End-use 2022-2032
- 6.1. Segment Dashboard
- 6.2. Revenue Trend Analysis by End-use, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Rehabilitation Centers
- 6.2.2. Clinics
- 6.2.3. Hospitals
Chapter 7. Global Substance Abuse Treatment Market Size & Forecasts by Region 2022-2032
- 7.1. North America Market
- 7.1.1. U.S. Market
- 7.1.1.1. Segment breakdown size & forecasts, 2022-2032
- 7.1.2. Canada Market
- 7.2. Europe Market
- 7.2.1. UK Market
- 7.2.2. Germany Market
- 7.2.3. France Market
- 7.2.4. Spain Market
- 7.2.5. Italy Market
- 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
- 7.3.1. China Market
- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
- 7.4.1. Brazil Market
- 7.4.2. Mexico Market
- 7.5. Middle East & Africa Market
- 7.5.1. Saudi Arabia Market
- 7.5.2. South Africa Market
- 7.5.3. Rest of Middle East & Africa Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. Mallinckrodt Pharmaceuticals
- 8.1.2. Pfizer Inc.
- 8.1.3. Teva Pharmaceuticals
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Mallinckrodt Pharmaceuticals
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. Pfizer Inc.
- 8.3.3. Teva Pharmaceuticals
- 8.3.4. Alkermes plc
- 8.3.5. Cipla Ltd.
- 8.3.6. Dr. Reddy's Laboratories Ltd.
- 8.3.7. Indivior PLC
- 8.3.8. Glenmark Pharmaceuticals
- 8.3.9. Amneal Pharmaceuticals Inc.
- 8.3.10. Apotex Inc.
- 8.3.11. Purdue Pharma L.P.
- 8.3.12. H. Lundbeck A/S
- 8.3.13. Sun Pharmaceutical Industries Ltd.
- 8.3.14. Viatris Inc.
- 8.3.15. BioCorRx Inc.
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
°ü·ÃÀÚ·á